Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
Status:
Active, not recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in
adolescent and adult participants with non-segmental vitiligo for whom total body involved
vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).